Abstract:Liraglutide is a GLP-1 receptor agonist recently approved for Type-II diabetes (T2D) treatment with superior hypoglycemic effect while also improving cardiovascular function for the patients. However, its application has been limited by its short half-life (~13 h), which requires daily injections to maintain effective drug concentrations in blood, thus increasing the risk of poor patient compliance and complications. In this study, we developed a ternary liraglutide/tannic acid (TA)/Al3+ nanoparticle system based on hydrogen bond formation between liraglutide and TA and stabilized by complex coordination interaction between TA and Al3+. This ternary nanoparticle formulation offers sustained release of liraglutide for >8 days by optimizing the concentration of TA during nanoparticle assembly. A flash nanocomplexation (FNC) process was adopted to confer homogeneous mixing of the three components and control the assembly kinetics, thus enabling efficient encapsulation, a tunable drug release profile, improved nanoparticle size uniformity, and a high degree of colloidal stability. Upon a single intraperitoneal (i.p.) administration, the optimized formulation effectively lowered the high blood glucose level in a T2D db/db mice model to the normal range (8-10 mmol/L) within 6 h, maintained it for 60 more hours, and kept it lower than the original level for >6 days. In a 30-day treatment study, the nanoparticle formulation with a dosage frequency of once every 5 days exhibited similar or better control of blood sugar level (20% reduction in HbA1c) and weight control than daily injection of free liraglutide at the same treatment dose. The extended glycemic control led to distinctive improvements on reducing cardiomyopathy, including inhibition in lipo-toxicity by decreasing 40% of triglyceride, 30% of diacylglycerol and 50% of PKC level in the heart, as well as ameliorating oxidative stress and cell apoptosis activities through positive regulation on superoxidase, malondialdehyde, caspase-3 and Bax. This nanoparticle system demonstrates improved therapeutic potential owing to its long-acting glycemic control with improved cardiovascular function and reduced tissue toxicity in multiple organs.

Underlying mechanism of Liraglutide in delaying the progression of type 2 diabetes:Evidence from China

Progress in the protective action of liraglutide on the islet β cells

[The Renal Protective Effect and Mechanism of Liraglutide in Diabetic Mice Induced by High-Fat Diet].

Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology

Liraglutide Attenuates Hepatic Oxidative Stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic Mice by Modulating the Wnt/β-Catenin Signaling Pathway

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.

Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus

Liraglutide: A Novel Therapy for Type 2 Diabetes——report of "diabetes Dialogue" International Forum

Effects of Liraglutide on Glycemic Gontrol in Metformin-Treated Patients with Type 2 Diabetes Mellitus

Liraglutide Ameliorates Beta-Cell Function, Alleviates Oxidative Stress and Inhibits Low Grade Inflammation in Young Patients with New-Onset Type 2 Diabetes

The Possible Benefits from Early Initiation and Long-Term Treatment of Liraglutide

Clinical efficacy and safety of Liraglutide in the treatment of obese or overweight patients with different duration of T2DM

Application of Glucagon-like Peptide-1 Analogue

The research of the treatment to type 2 diabetes mellitus (T2DM) by lixisenatide

Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux

Liraglutide Ameliorates Glycometabolism And Insulin Resistance Through The Upregulation Of Glut4 In Diabetic Kkay Mice

Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes

A polyphenol-metal nanoparticle platform for tunable release of liraglutide to improve blood glycemic control and reduce cardiovascular complications in a mouse model of type II diabetes

Short-term Cost-effectiveness of Liraglutide Versus Rosiglitazone、Glimepiride、Exenatide and Insulin Glargine in Chinese Patients with type 2 Diabetes

Improved glycemic control and reduction of cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes and metabolic syndrome treated with liraglutide